[ad_1]
Astra Zeneca pays with both money and shares, a total equivalent to $ 175 per share in Alexion. This is clearly more than Friday’s closing price of $ 121 and means that the total acquisition price will be $ 39 billion, which corresponds to just over 330 billion kronor.
The boards of both companies approved the plans, but since approval from owners and authorities is also required, the purchase is expected to be completed during the third quarter of next year.
Minimal vaccine
“The acquisition allows us to be even stronger in immunology. We look forward to welcoming our new colleagues to Alexion so that together we can build on our combined expertise,” said Pascal Soriot, CEO of Astra Zeneca, in a press release.
The companies have been talking about an acquisition for “several months,” and the deal will have minimal impact on Astra Zeneca’s work with a COVID-19 vaccine, Soriot told The Wall Street Journal.
Believe in profit growth
Astra Zeneca estimates that the acquisition could lead to a spending reduction of $ 500 million per year through efficiencies, synergies and savings. The company also expects a double-digit percentage increase in earnings over the next three years.
Last year, Alexion had just over 3,000 employees and a turnover of about $ 5 billion, an increase of 21 percent over 2018. The Boston-based company specializes in drugs for very illnesses. unusual. With the acquisition, Astra Zeneca establishes Boston as the headquarters of unusual diseases.
Fixed: In a previous version of the text, there was an incorrect statement about Alexion’s rotation.
[ad_2]
